


Sophia G. Antimisiaris, Bpharm, Ph.D



Current Position

Professor of Pharmaceutics, Department of Pharmacy, University of Patras, 26500 Rio, Greece

Collaborating Faculty member, Institute of Chemical Engineering, ICEHT/FORTH

<http://www.pharmacy.upatras.gr/ErgPharmTechno.htm>

<http://www.iceht.forth.gr/about.html>

Personal

Place and Date of Birth	New Jersey, USA, 1962
Marital Status	Married, two children
Address	Rio 26510, Greece
Tel	+30-2610-962332 mob:6937503020
Fax	+30-2610-992330
e-mail	santimis@upatras.gr

Education

1980-1984

Department of Pharmacy,
School of Health Scienc, University of Athens, Greece,

Degree: BPharm (8.4/10)

1984-1988

Department of Pharmacy,
School of Health Scienc, University of Athens, Greece,

Degree: PhD (Biopharmaceutics)
Supervisor: Prof. P. Macheras

Affiliations

1988-1989	Postdoctoral Research Assistant. School of Pharmacy, University of South California, Laboratory of Prof. Karl H.L. Hwang, Research on Liposomal Drug Delivery and Targeting.
1989-1993	Lecturer of Pharmaceutics, Department of Pharmacy, University of Patras (UPAT).
1992-1993	(Sabbatical leave from UPAT) Visiting Professor, School of Pharmacy, University of London, Laboratory of Prof. Gregory Gregoriadis, Research on Liposomal Vaccine Delivery.
1993-2002	Assistant Prof, Department of Pharmacy, UPAT
2002-10	Associate Prof, Department of Pharmacy, UPAT
2006-	Collaborating Member, Institute of Chemical Engineering, ICEHT-FORTH
2010/2013-	Professor, Department of Pharmacy, UPAT

Research Activities

MORE THAN 25 YEARS OF EXPERTISE IN THE AREAS

- Nanomedicines: Liposomal systems for Controlled Drug (or Vaccine) Delivery and/or Targeting
- Biopharmaceutics and Pharmacokinetics: Improving Drug Biodistribution and Pharmacokinetics through Advanced Drug Delivery System Design
- Application of novel lipid vesicles (Arsonoliposomes) in Anticancer / Antiparasitic Therapeutics.
- Novel Controlled-(Release)-Drug-Eluting Surfaces
- Skin (dermal &transdermal), Ocular, Alveolar and Vaginal Drug Delivery Systems

- Elastic Liposomes for penetration in the skin
- Nanoliposomes to target the brain, for Cancer or Alzheimer's disease, diagnosis and/or therapy

Participation in Research Projects-FUNDING

Participation as coordinator and/or PI in 2 National (GSRT & Ministry of Education) funded; 8 European Commission funded, and industry funded programmes, including:

- Marie-Curie Marie Curie Early Stage Scholarship Program, project name: Towards a Euro-PhD in Advanced drug delivery, contract no: MEST-CT-2004 - 504992 (FP6) [2004-2008, Host lab with 3 one-year scholarships (120.000 euro)] (Role: PI, Host Lab)
- Socrates mobility and Intensive Program Training Projects [1997, 2000, 2003 and 2008 (>50.000 euro total)]
- Integrated Project (FP6-Health) [contract number LSHP-CT-2004-503162 (Selection and Development of Microbicides for Mucosal Use to Prevent Sexual HIV Transmission/Acquisition) SHIVA 2004-2009 (430.000 euro)] (Role: PI, WP-leader)
- INTEREG III program [2006-2008 (120.000 euro)] (Role: partner)
- Industry-funded projects [2005, 2007, 2014-] (Role: Coordinator/PI)
- Large scale program in NMP (Nanotechnology-Materials-Processes) FP7 [NAD (Nanoparticles for therapy and Diagnosis of Alzheimers disease/NAD Grant Agreement No. 212043) 2008-2013 (800.000 euro)]. (Role: PI, WP-leader)
- Industry funded projects 2015, 2016

Teaching Activities

1989- *Undergraduate Program (Pharmacy Dept):* Biopharmaceutics and Pharmacokinetics (+Practical course) Pharmaceutical Technology: Pre-Formulation / Design and Preparation of Drug Formulation.(+Practical course)

1995 - *Postgraduate Program (Pharmacy Dept):* Applied Pharmacokinetics, Determination of Drugs in Biological Fluids, Pharmaceutical Statistics, Advanced-Novel Pharmaceutical Formulations (Liquid, Semi-Solid, Solid)

2000 - *Postgraduate Program (School of Medicine):* Pharmacokinetic Modeling / Modulating Drug Pharmacokinetics by Advanced Drug Delivery Systems

For the Socrates Educational Program "Novel Drug Delivery Systems: 10-day Workshop entitled: Liposome Technology and Applications in Therapeutics (1997-98, 1999-2000).

Prizes-Honors

1980-1984: Scholarships from Greek State Scholarships' Foundation (IKY) for outstanding performance during undergraduate studies (Ranking in top 5% of class)

1988-89: Research Fellowship, University of South. California (NIH), L.A, USA

1992-93: Research Fellowship, University of London (from MOD funded project), London, UK.

Professional Affiliations

- Panhellenic Association of Pharmacists
- APGI/APV (Association de Pharmacie Galenique Industrielle)
- European Federation of Pharmaceutical Scientists (EUFEPS)
- AAPS (Americal Association of Pharm. Scientists)
- Controlled Release Society (CRS)
- CRS -Greek Chapter [President 1999-2001]

- International Liposome Society (ILS)
- Galenos Network for novel Drug delivery Exploitation and Education

Professional Activities

Associate Editor Europe for the Journal of Biomedical Nanotechnology (2006-).
 Member of Editorial Board of Journal of Drug Delivery (2010 -).
 Referee for >40 Pharmaceutical and related Scientific journals.
 Participation in Research Proposal Evaluation panels/mid-term Reviewes (& Panel Rapporateur), European Commission, Research Directorate, 2003, 2004 (FP6), 2007 (FP7), 2015 (Horizon 2020).
 Evaluator for the Spanish Ministry of Development and Research (after invitation), *Evaluatores*, 2006, and for a number of other foundations (TWAS, Israel Research Council, British cancer Research foundation, Dutch research foundation etc.)
 President of the Western-Greece Committee for evaluation of Pharmacy Technicians (2001-).
 Evaluator for the National Foundation of Drugs (EOF) for Clinical Studies and Formulation Bioequivalence Studies (2000-).
 Member of Scientific Committee of the International Conference of European Association of Pharma Biotechnology [EAPB] (2004).
 Member of Scientific Advisory Board Europe, of New Drugs, official publication of EAPB (2004).
 Member of the Senate, Univ. of Patras (2004-5).
 Member of the Graduate Studies committee, Dept. of Pharmacy, Univ. of Patras (1998-).
 Coordinator of the Erasmus mobility Program for the Dept. of Pharmacy, Univ. of Patras (1998-).

PUBLICATIONS

98 papers in peer-reviewed journals (or series), 19 Invited Papers & Reviews or Chapters in Book Series, 180 Abstracts in proceeding of National, European and International conferences, 6 Papers in Greek Scientific Journals, 1 World patent, 1 PCT application and 3 Greek patents. Books: 1 Textbook on Biopharmaceutics and Pharmacokinetics (in Greek) and 2 Practical course textbooks (in Greek).

Conference Participation/Attendance

Participation in > 150 International conferences or educational workshops, and > 50 National conferences; Invited speaker in 47 National and International scientific or educational meetings/workshops/conferences. More than 137 abstracts/presentations is conferences.

Publications (peer-reviewed in journals / book series) (from 2009 with IF)

1. P. Macheras, M. Koupparis, S.G. Antimisiaris, " *Effect of Temperature and Fat content on the binding of Hydrochlorothiazide and Chlorothiazide to milk*", **J Pharm Sci-US**, 77, 334-336, (1988).
2. P. Macheras, M. Koupparis, S.G. Antimisiaris, " *Effect of Temperature and Fat content on the Solubility of Hydrochlorothiazide and Chlorothiazide in Milk*", **J Pharm Sci-US**, 78, 933-936, (1988)
3. P. Macheras, M. Koupparis, S.G. Antimisiaris, " *An in-vitro model for exploring CR Theophylline-milk fat Interactions*", **Int.J. Pharm.**, 54, 123-129, (1989).
4. P. Macheras, M.Koupparis, S.G. Antimisiaris, " *Drug Binding and Solubility in Milk*", **Pharm. Research**, 8, 537-541, (1990).
5. P. Macheras, C. Reppas, S.G. Antimisiaris, " *Binding of drugs in milk : The role of Casein in Milk Protein Binding [letter]*", **Pharm. Research**, 8, 550, (1991).

6. S. G. Antimisiaris, Jayasekera,P., Gregoriadis,G., "Liposomes as vaccine carriers: Incorporation of soluble and particulate antigens in giant vesicles", **J. Immunol. Methods**, 166, 271-280, (1993).
7. Gursel, I. Antimisiaris, S.; Jayasekera, P.; Gregoriadis, G. "Giant liposomes as potential vesicles for live or attenuated microbial vaccines", **Drug Targeting and Delivery**, 6 , 35-50, (1995).
8. C.G. Kontoyannis, S.G. Antimisiaris, D. Douroumis, «Simultaneous quantitative determination of diazepam and liposomes using differential pulse polarography», **Anal. Chim. Acta**, 391, 83-88, 1999.
9. C.G. Kontoyannis, S.G. Antimisiaris, D. Douroumis, «Quantitative determination of the non-entrapped chlorothiazide in the presence of liposomes using differential pulse polarography», **Talanta**, 48, 979-983, 1999
10. M. Kokona, P. Kallinteri, D. Fatouros, S. G. Antimisiaris*, «Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: Effect of lipid composition . **Eur. J. Pharm. Sciences**, 9, 245-252, 2000.
11. Antimisiaris, S.G., Siablis, Liatsikos, E., Kalogeropoulou, C., Tsotas, V, Tsota E, Karnabatidis, Fatouros D.G., Barbalias, «Preparation and in-vitro evaluation of liposome covered stents for use as ureteral stents», **J. Endourology**, 14:9, 743-747, 2000.
12. E. Papadimitriou and S.G. Antimisiaris*, «Interactions of PC/Chol and PS/Chol liposomes with human cells in vitro», **J. Drug Targeting**, 8:5, 335-351 2000.
13. D. Fatouros, S.G. Antimisiaris*, «Physicochemical properties of liposomes incorporating hydrochlorothiazide and chlorothiazide», **J. Drug Targeting**, 9:1, 61-74, 2001
14. P. Kallinteri, W-Y. Liao, S.G. Antimisiaris* and K.H.L. Hwang, «Characterization, Stability and in-vivo distribution of Fetuin F2 glycopeptide incorporating DSPC/Chol liposomes prepared by mild cholate incubation, **J.Drug Targeting**, 9:2, 155-168, 2001.
15. D. Fatouros, O. Gortzi, P. Klepetsanis, S.G. Antimisiaris*, M.C. Stuart, A. Brisson, P. V, Ioannou, «Preparation and properties of arsonolipid containing liposomes», **Chem. Phys. Lipids**, 109, 75-89, 2001.
16. Fatouros, K. Haztidimitriou, S.G. Antimisiaris*, «Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: comparison of membrane integrity and drug release», **Eur. J. Pharm. Sciences**, 13, 287-296, 2001
17. Paraskevi Kallinteri, Sophia G. Antimisiaris*, 'Solubility of drugs in the presence of gelatin: effect of drug lipophilicity and degree of ionization», **Int. J. Pharm.**, 221, 219-226, 2001.
18. Gortzi, P. Klepetsanis, S.G. Antimisiaris*, P. V. Ioannou, «Capability of arsonolipids to transport divalent cations: A pressman cell study », **Chem. Phys. Lipids**, 112, 21-29, 2001.
19. Paraskevi Kallinteri, Euangelia Papadimitriou, Sophia G. Antimisiaris*, «Targeting of small unilamellar liposomes bearing asialofetuin glycopeptide conjugates to HepG₂ cells», **J. Liposome. Res.**, 11(2&3), 175-193, 2001
20. Olga Gortzi, Evangelia Papadimitriou, Christos G. Kontoyannis, Sophia G. Antimisiaris* and Panayiotis Ioannou, «Arsonoliposomes, a novel class of arsenic containing liposomes: Effect of palmitoyl-arsonolipid containing liposomes on the viability of various cancer and normal cells in culture», **Pharm. Research**, 19:1, 79-86, 2002.
21. Dimitris Fatouros, S.G.Antimisiaris*, «Effect of Amphiphilic drugs on the Stability and Zeta-Potential of their liposome formulations: A study with Prednisolone, Diazepam and Griseofulvin», **J. Coll. Inter. Scienc.**, 251, 271-277, 2002.

22. P. Kallinteri, S.G.Antimisiaris*, I. Tsota, C. Kalogeropoulou, D. Karnabatidis, D. Siablis, «*Dexamethasone incorporating liposomes: An in vitro study of their applicability as a slow release delivery system of dexamethasone from covered metallic stents*», **Biomaterials**, 23, 4819-4826, 2002.
23. Katharios Pantelis, Antimisiaris Sophia, Pavlidis Michalis & Iliopoulou-Georgudaki Joan, «*Serum pharmacokinetics of ivermectin in sea bream, sparus aurata using a direct competitive elisa.*» **Fish Physiol Biochem** 26 (2): 189-195, 2003.
24. Olga Gortzi, Evangelia Papadimitriou, Sophia G. Antimisiaris* and Panagiotis Ioannou, «*Cytotoxicity of arsonolipid containing liposomes towards cancer and normal cells in culture: Effect of arsonolipid acyl chain length*», **Eur. J. Pharm. Sciences**, 18, 2, 175-183, 2003.
25. Sophia G. Antimisiaris*, Panayiotis V. Ioannou, Philippe M. Loiseau «*In vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in vivo distribution*» **J. Pharmacy and Pharmacology**, 55 (5): 647-652, 2003
26. Katharios P., Iliopoulou-Georgudaki J., Antimisiaris S., Verri T., Toma P., Acierno R., and Maffia M. *Pharmacokinetics of cephalexin in sea bream, Sparus aurata (L.) after a single intraperitoneal injection.* Journal of Applied Ichthyology. **J Appl Ichthyol.** 20 (5): 422-426, 2004
27. P. Kallinteri, D. Fatouros, P. Klepetsanis, S. G. Antimisiaris*, «*Arsenic trioxide liposomes. Encapsulation efficiency and in vitro stability*, **J. Liposome Res.**, 14 (1-2): 27-38, 2004
28. Antimisiaris SG*, Klepetsanis P, Zachariou V, et al. *In vivo distribution of arsenic after i.p. injection of arsonoliposomes in balb-c mice.* **Int J Pharm** 289 (1-2): 151-158, 31 2005
29. Fatouros DG, Piperoudi S, Gortzi O, Ioannou PV, Antimisiaris SG.*. *Physical stability of sonicated arsonoliposomes: Effect of calcium ions.* **J Pharm Sci-US** 94 (1): 46-55, 2005
30. Fatouros DG, Klepetsanis P, Ioannou PV, Antimisiaris SG. *The effect of pH on the electrophoretic behaviour of a new class of liposomes: arsonoliposomes.* **Int J Pharm** 288 (1): 151-156 , 2005
31. Fatouros DG, Bouropoulos N, Ioannou PV, Antimisiaris SG. *Stability and aggregation studies of non-sonicated arsonolipid-containing vesicles,* **Cell Mol Biol Lett** 10 (1): 173-183 2005
32. S.Piperoudi, P.V.Ioannou, P.Frederik, S.G.Antimisiaris*, *Arsonoliposomes: Effect of lipid composition on their stability.* **J Liposome Res** 15 (3-4): 187-197 2005
33. Sophia Piperoudi, Dimitris Fatouros[&], Panayiotis V. Ioannou, Peter Frederik, Sophia G. Antimisiaris*, *Incorporation of PEG-lipids in arsonoliposomes can produce highly stable arsenic-containing vesicles of specific lipid composition.* **Chem. Phys. Lipids** 139:2, 96-106, 2006.
34. G. Koromila, G. Michanetzis, Y.F. Missirlis, and S.G.Antimisiaris*, *Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: Effect on haemocompatibility,* **Biomaterials**, 27:12, 2525-2533, 2006.
35. S. Koutsopoulos, DG. Fatouros, PV. Ioannou, SG Antimisiaris. *Thermal behaviour of non-sonicated arsonolipid Dispersions.* **Biophysical Chemistry**, 121:2, 150-54, 2006
36. D.Fatouros ,PV Ioannou, SG Antimisiaris*. *Novel Nanosized Arsenic Containing Vesicles For Drug Delivery: Arsonoliposomes.* (Invited Review article) **J. Nanoscience & Nanotechnology**, 6: 2618-2687, 2006
37. M. Haikou, P. Zagana, PV, Ioannou and SG. Antimisiaris*. *Arsonoliposome Interaction with thiols. Effect of pegylation and arsonolipid content on their integrity during incubation in the presence of glutathione.* **J. Nanoscience & Nanotechnology**, 6: 2974-2978, 2006

38. S.G.Antimisiaris*, G. Koromila, G. Michanetzis, Y.F. Missirlis, Liposome coated stents: *A method to deliver drugs to the site of action and improve stent blood-compatibility*. (Invited paper) **Journal of Liposome Research**, Volume 16, Number 3, 303-309, 2006
39. V. Ntimenou, S. Mourtas, E. Christodoulakis, M. Tsilimbaris, S.G. Antimisiaris*. *Stability of protein encapsulating DRV liposomes after freeze drying: A study with BSA and t-PA*. **J Liposome Research**, Volume 16, Number 4, 403-416, 2006
40. P. Hatzi, S. Mourtas, P. Klepetsanis, S.G Antimisiaris*. *Integrity of liposomes in presence of cyclodextrins. Effect of liposome type and lipid composition*, **Int. J. Pharm** ,333 (1-2), pp. 167-176, 2007.
41. S. Mourtas, S. Fotopoulou, S. Duraj, V. Sfika, C. Tsakiroglou, S.G. Antimisiaris*.. *Liposomal drugs dispersed in Hydrogels. Effect of liposome, drug and gel properties on drug release kinetics*. **Colloids and Surf B: Biointerfaces**, 55 (2), pp. 212-221 , 2007.
42. Vassilios-Athanassios Tsotas, Spyridon Mourtas and Sophia G. Antimisiaris* *Dexamethasone incorporating liposomes: Effect of lipid composition on drug trapping efficiency and vesicle stability*. **Drug Delivery**, 14(7), 441-445, 2007
43. M. Zaru, S. Mourtas, P. Klepetsanis, A.M. Fadda and S.G.Antimisiaris*, *Liposomes for drug delivery to the lungs after nebulization*. **Eur. J. Pharmac & Biopharmac**, 67 (3), 655-666, 2007
44. Sophia G. Antimisiaris*, Commentary: *FP7 funding possibilities for the area of Biomedical Nanotechnology*, **J Biomedical Nanotechnology**, 3(3), 297-299, 2007
45. Paraskevi Zagana, Pavlos Klepetsanis, Panayiotis V. Ioannou, Philippe M. Loiseau, S.G. Antimisiaris* « *Trypanocidal activity of arsonoliposomes: Effect of vesicle lipid composition*», **Biomedicine & Pharmacotherapy**, 61, 499-504,2007
46. P. Zagana, M. Haikou, P. Klepetsanis, E. Giannopoulou, P.V. Ioannou, S.G. Antimisiaris, *In vivo distribution of arsonoliposomes: Effect of vesicle lipid composition*, **Int. J. Pharm**, 347 (1-2), 86-92, 2008
47. S.G.Antimisiaris*, *Arsonoliposomes for Drug Delivery*, **J. Drug Del Scienc & Techn** 17, 377-388, 2007
48. S. Mourtas, S. Duraj, S. Fotopoulou, S.G. Antimisiaris*. *Integrity of liposomes in presence of various formulation additives, in aqueous dispersions and in hydrogels*, **Colloids and Surf B: Biointerfaces**, 61 (2), 270-276, 2008
49. Maria Letizia Manca , Spyridon Mourtas, Vassilios Drakopoulos, Anna Maria Fadda, Sophia G.Antimisiaris*, *PLGA, Chitosan or Chitosan-coated PLGA Microparticles for Alveolar Delivery? A comparative study of particle stability during nebulization*. **Colloids and Surf B: Biointerfaces**, 62 (2), 220-231, 2008
50. Spyridon Mourtas, Maria Haikou, Maria Theodoropoulou, Christos Tsakiroglou and Sophia G. Antimisiaris*, *How liposome type, composition and loading concentration influence the rheological properties of a liposomal gel*. **J. Colloid & Inter. Scienc B: Biointerfaces**, 317 (2), 611-619, 2008
51. C. Peptu, M. Popa, S.G. Antimisiaris*, *Release of Liposome-Encapsulated Calcein from Liposome Entrapping Gelatin-Carboxymethylcellulose Films: A Presentation of Different Possibilities*. **J. Nanoscience & Nanotechnology**, 8, 2249–2258, 2008
52. P. Zagana, M. Haikou, E. Giannopoulou, P.V. Ioannou, S.G. Antimisiaris*, *Arsonoliposome Interaction with cells in culture. Effect of pegylation and lipid composition*. Invited contribution, **J. Mol. Nutr. Food Res**. 53, 592 – 599, 2009

53. Maria Letizia Manca, Giuseppe Loy, Marco Zaru, Anna Maria Fadda, Sophia G. Antimisiaris* *Release of Rifampicin from Chitosan, PLGA and Chitosan-coated PLGA microparticles*, **Colloids and Surf B: Biointerfaces**, 67, 166-170, 2008
54. Sophia G. Antimisiaris, Guest Editor, **A Special Issue on Nanomedicines**, **J. Biomed. Nanotechnol.** 4, 217, 2008
55. Georgios P. A. K. Michanetzis, Yannis F. Missirlis, and Sophia G. Antimisiaris* *Haemocompatibility of Nanosized Drug Delivery Systems: Has It Been Adequately Considered?* **J. Biomed. Nanotechnol.** 4, 218-233, 2008
56. Marco Zaru, Maria-Letizia Manca, Anna Maria Fadda Sophia G. Antimisiaris* *«Chitosan-coated liposomes for delivery to lungs by nebulization»*. **Colloids& Surf B: Biointerfaces** 71 (1), 88-95 , 2009 [IF=4.15]
57. S. Mourtas, C. Aggelopoulos, P. Klepetsanis, C. Tsakiroglou, S.G. Antimisiaris*, *“Complex gel formulations for topical drug administration: Rheological properties and aging”*, **Langmuir**, 25 (15), pp. 8480-8488, 2009 [IF=4.45]
58. S. Mourtas*, G. PA Michanetzis, Y. F. Missirlis and S.G Antimisiaris. *Haemolytic activity of lipidic carriers: Effect of vesicle size, lipid concentration and PEG-lipid or arsonolipid incorporation*. **J Biomed Nanotechnology** 5, 409-415, 2009[IF=5.25]
59. Antimisiaris, S.G. *Arsonoliposomes for drug delivery applications*, **Clinical Lipidology** 4 (5), pp. 663-675, 2009
60. Favretto, M.E., Marouf, S., Ioannou, P., Antimisiaris, S.G., Parker, T.L. Kallinteri, P. *Arsonoliposomes for the potential treatment of medulloblastoma*, **Pharm. Research** 26 (10), 2237-2246 2009 [IF=4.25]
61. S.G.Antimisiaris, *“Preparation of DRV liposomes”*, **Methods in molecular biology** (Clifton, N.J.) (2010), **605**, 51-75. ISBN: 978-1-60327-359-6.
62. S.G.Antimisiaris*, P.V. Ioannou, *“Arsonoliposomes: preparation and physicochemical characterization”*, **Methods in molecular biology** (Clifton, N.J.) (2010), **605**, 147-62. ISBN: 978-1-60327-359-6.
63. G. Besson, M. Caron, S. Lekana-Douki Etenna, A. Mints-Ndong, S. Mourtas, B. Sallé, C. De Giuli Morghen, P. LaColla, S. Antimisiaris M. Kazanji *“Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus Macaques with RT SHIV”*, **Virology** 405 (1), 225-233, 2010 [IF=3.35]
64. E Markoutsas, G Pampalakis, A Niarakis, I. A. Romero, B. Weksler, P-Or Couraud, S. G. Antimisiaris*, *Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line*, **EJPB**, 77: 2, 265-274, 2011[IF=4.25]
65. S. Mourtas, M. Canovi, C. Zona, D. Aurilia, A. Niarakis, B. La Ferla, M. Salmona, F. Nicotra, M. Gobbi, S. G. Antimisiaris*, *Curcumin-decorated nanoliposomes with very high affinity for amyloid-b1-42 peptide*, **Biomaterials**, 32: 6, 1635-1645, 2011[IF=7.62]
66. S. Mourtas, M. Kastellorizios P. Klepetsanis, (...), S. Antimisiaris*. *Immobilization of liposomes on Plasma-treated stainless steel surfaces, by covalent binding*. **Colloids& Surf B: Biointerfaces**, 84 (1), 214-220, 2011[IF=4.15]
67. Canovi, M., Markoutsas, E., Lazar, A.N., Pampalakis, G., Clemente, C., Re, F., Sesana, S., (...), Antimisiaris, S.G* *The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue*. **Biomaterials** 32 (23), pp. 5489-5497, 2011 [IF=7.62]

68. Stolte-Leeb N, Loddo R, Antimisiaris S, Schultheiss T, Sauermann U, Franz M, Mourtas S, Parsy C, Storer R, Colla PL, Stahl-Hennig C *Topical Nnucleoside Reverse Transcriptase Inhibitor MC 1220 Partially Prevents Vaginal RT-SHIV Infection of Macaques*. **AIDS Res Hum Retroviruses**. 27 (9) , pp. 933-943, 2011. [IF=2.72]
69. M-T Popescu, S Mourtas, G Pampalakis, S G. Antimisiaris, C Tsitsilianis. *pH-Responsive Hydrogel/Liposome Soft Nanocomposites For Tuning Drug Release*, **Biomacromolecules**, 12 (8) , pp. 3023-3030, 2011. [IF=5.75]
70. S. Mourtas, P. Klepetsanis, (...), and S.G. Antimisiaris*. Liposomal gels for vaginal delivery of the microbicide MC1220: Preparation and in vivo vaginal toxicity and pharmacokinetics, **NanoLife** Volume: 1, Issues: 3-4(2010) pp. 195-205
71. A.Skouras, S. Mourtas, E. Markoutsas, M-C. De Goltstein, C Wallon, S Catoen, SG. Antimisiaris*. USPIO encapsulating nanoliposomes with high entrapping efficiency, stability and magnetic properties. **Nanomedicine: Nanotechnology, Biology and Medicine**, 7 (5) , pp. 572-579, 2011[IF=6.69]
72. M. Taylor, S Moore, S Mourtas, A Niarakis, F Re, C Zona, B. la Ferla, F. Nicotra, M. Masserini, S G Antimisiaris, M Gregori, David Allsop. Effect of curcumin-associated and lipid ligand functionalised nanoliposomes on aggregation of the Alzheimer's A β peptide. **Nanomedicine: Nanotechnology, Biology, and Medicine** 7 (5), pp. 541-550, 2011. [IF=6.69]
73. E. Markoutsas, K. Papadia, C. Clemente, O. Flores, S.G. Antimisiaris*. *Anti-A β MAb and dually-decorated nanoliposomes: Effect of A β 1-42 peptides on interaction with hCMEC/D3 cells*, **European Journal of Pharmaceutics and Biopharmaceutics** 81 (1) , pp. 49-56, 2012. [IF=4.25]
74. M. Kastellorizios, G. P.A.K. Michanetis, B.R. Pistillo, S. Mourtas, P. Klepetsanis, P. Favia, E. Sardella, R. d'Agostino, Y. F. Missirlis, S. G. Antimisiaris*. Improving the haemocompatibility of metallic surfaces by covalent binding of heparin-encapsulating functionalized liposomes. **International Journal of Pharmaceutics** 432 (1-2) , pp. 91-98, 2012. [IF=3.55]
75. Vassiliki Ntimenou, Alfred Fahr, and Sophia G. Antimisiaris* *Elastic Vesicles for Transdermal Drug Delivery of Hydrophilic Drugs: A Comparison of Important Physicochemical Characteristics of Different Vesicle Types* **J. Biomed. Nanotechnol.** 8, 613-623, 2012. [IF=7.57]
76. Svarnas, P., Matrali, S.H., Gazeli, K., Aleiferis, S., Clément, F., Antimisiaris, S.G.* Atmospheric-pressure guided streamers for liposomal membrane disruption. **Applied Physics Letters** 101 (26) , art. no. 264103, 2012. [IF=3.79]
77. Adina Lazar, Spyridon Mourtas, Ihsen Youssef, Christophe Parizot, Aurélien Dauphin, Benoît Delatour, Sophia G Antimisiaris, Charles Duyckaerts. *Curcumin-conjugated nanoliposomes with high affinity for A β deposits: possible applications to Alzheimer disease* **Nanomedicine: Nanotechnology, Biology, and Medicine**, 9 (5), pp. 712-721, 2013. [IF=6.69]
78. Konstantina Papadia, Eleni Markoutsas, and Sophia G. Antimisiaris*. *A Simplified Method to Attach Antibodies on Liposomes by Biotin-Streptavidin Affinity for Rapid and Economical Screening of Targeted Liposomes* **J. Biomed. Nanotechnol.** 10, 871-876, 2014. [IF=7.57]
79. Antimisiaris, S.G. Potential of nanoliposomes for the therapy and/or diagnosis of Alzheimer's disease: Recent progress (Note), *Clinical Lipidology*, Volume 9, Issue 5, 477-481, 2014 [IF=0.87]
80. E. Markoutsas, K. Papadia, A.T. Giannou, M. Spella, A. Cagnotto, M. Salmona, G.T. Stathopoulos, S. G. Antimisiaris* *Mono and Dually Decorated Nanoliposomes for Brain Targeting, In Vitro and In Vivo Studies*, **Pharm Research**, 31, 5, 1275-1289, 2014 [IF=3.42]
81. Spyridon Mourtas, Adina N. Lazar, Eleni Markoutsas, Charles Duyckaerts, Sophia G. Antimisiaris*. *Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease*, **European Journal of Medicinal Chemistry**, 80, 175-

183, 2014 [IF=3.45]

82. Cristina Airoidi, Spyridon Mourtas, Francisco Cardona, Cristiano Zona, Erika Sironi, Giuseppe D'Orazio, Eleni Markoutsas, Francesco Nicotra, a Sophia G. Antimisiaris, Barbara La Ferla. *Copper-free click surface decorated nanoliposomes with a glycodeived ligand display binding affinity and aggregation inhibition ability towards amyloid β -1-42 peptide*, **European Journal of Medicinal Chemistry**, 85, 43-50, 2014 [IF=3.45]
83. H. Matloob, S. Mourtas, P. Klepetsanis, S. G. Antimisiaris*, Increasing the stability of curcumin in serum with liposomes or hybrid drug-in-cyclodextrin-in-liposome systems: A comparative study, *International Journal of Pharmaceutics*, 476, 1–2, 108–115, 2014 [IF=3.65]
84. Antimisiaris, S.G* Mourtas, S., Markoutsas, E., Skouras, A., Papadia, K. Nanoparticles for Diagnosis and/or Treatment of Alzheimer's Disease (Book Chapter), **Advanced Healthcare Materials**, Pages 87-179, 2014
85. Panagiotis Svarnas, Sophia H. Matrali, Kristaq Gazeli and Sophia G. Antimisiaris. Assessment of Atmospheric-Pressure Guided Streamer (Plasma Bullet) Influence on Liposomes with Different Composition and Physicochemical Properties, **Plasma Process. Polym** 2015 [IF=3.73]
86. Antimisiaris, S.G*, Mourtas, S.Recent advances on anti-HIV vaginal delivery systems development, **Advanced Drug Delivery Reviews**, 92 (2015) 123–145 [IF=15.040]
87. P Svarnas, SH Matrali, K Gazeli, SG Antimisiaris* Cover Picture: **Plasma Process. Polym**, 2015 [IF=3.73]
88. E Markoutsas, S Mourtas, E Bereczki, C Zona, B La Ferla, F Nicotra, ...SG Antimisiaris*, Comparison of Various Types of Ligand Decorated Nanoliposomes for their Ability to Inhibit Amyloid Aggregation and to Reverse Amyloid Cytotoxicity. **Current topics in medicinal chemistry** 15 (22), 2267-2276, 2015 [IF=3.45]
89. S Mourtas, G Diamanti, A Foka, V Dracopoulos, P Klepetsanis, V Stamouli, I. Spiliopoulou, SG Antimisiaris*. Inhibition of Bacterial Attachment on Surfaces by Immobilization of Tobramycin-Loaded Liposomes, **Journal of Biomedical Nanotechnology** 11 (12), 2186-2196, 2015 [IF=5.35]
90. ML Bondi, E Amore, C Botto, A Cordeiro, A Cusimano... **Frontiers in Nanomedicine-** 2015
91. K. Papadia, E. Markoutsas, S.G. Antimisiaris*. How do the physicochemical properties of nanoliposomes affect their interactions with the hCMEC/D3 cellular model of the BBB? **Int. J. Pharmaceutics**, 509 (1–2), 431–438, 2016 [IF=3.994]
92. K. Terzi, A. Sikinioti-Lock, A. Gkelios, D. Tzavara, A. Skouras, C. Aggelopoulos, P. Klepetsanis, S. Antimisiaris, C.D. Tsakiroglou. Mobility of zero valent iron nanoparticles and liposomes in porous media. **Colloids and Surfaces A: Physicochem. Eng. Aspects** 506 (2016) 711–722 [IF=2.108]
93. Antimisiaris, S.G. Preparation of DRV liposomes. *Methods in Molecular Biology*, 1522, 23-47 2017
94. Aloisio, C., Antimisiaris, S.G., Longhi, M.R. Liposomes containing cyclodextrins or meglumine to solubilize and improve the bioavailability of poorly soluble drugs. *J Mol. Liquids*, 229:106-113 2017 [IF=2.740]
95. K. Papadia., E.Markoutsas., S. Mourtas, A. Giannou, B. La Ferla, F. Nicotra, M. Salmona, G.T. Stathopoulos, S. G. Antimisiaris*, Multifunctional LUV liposomes decorated for BBB and amyloid targeting. A. In vitro proof-of-concept, **Eur. J. Pharm. Sciences**, 101:140-148, 2017. [IF=3.773]
96. S. Antimisiaris*, S. Mourtas, K. Papadia, Targeted si-RNA with liposomes and exosomes (extracellular vesicles): How to unlock the potential. **Int. J. Pharm**, in press, 2017, [IF=3.994]

97. K. Papadia, A. D. Giannou, E. Markoutsas, C. Bigot, G. Vanhoute, S. Mourtas, A. Van der Linden, G. T. Stathopoulos, S. G. Antimisiaris*. Multifunctional LUV liposomes decorated for BBB and amyloid targeting - B. In vivo brain targeting potential in wild-type and APP/PS1 mice, **Eur. J. Pharm. Sciences** 102, 180-187; **2017 [IF=3.773]**
98. T. Agaloti, A. D. Giannou, A.C. Krontira, N. I. Kanellakis, D. Kati, M. Vreka, M. Pepe, M. Spella, I. Lilis, D.E. Zazara, E. Nikolouli, N. Spiropoulou, A. Papadakis, K. Papadia, A. Voulgaridis, V. Harokopos, P. Stamou, S. Meiners, O. Eickelberg, L. A. Snyder, S. G. Antimisiaris, D. Kardamakis, I. Psallidas, A. Marazioti, and G.T. Stathopoulos. Mutant KRAS promotes malignant pleural effusion formation. **Nature Communications**, accepted **2017 [IF=11.329]**

Book Chapters

- G. Gregoriadis, I. Gursel and S. G. Antimisiaris, "Microbe entrapment in giant Liposomes", In : Nonmedical Applications of Liposomes (eds. L. Lasic and Y. Barenholz) CRC-Press, Boca Raton, pg. 263-269, 1996
- S. G. Antimisiaris*, D. Fatouros and P. Kallinteri. Invited Chapter on Liposome Technology, for the Pharmaceutical Manufacturing Handbook, Section 5: New Dosage Forms, Chapter 5.3, Eds. John Wiley and Sons, pp. 443-533, 2008
- S. G. Antimisiaris*. Lipid based nanoparticles for Drug Delivery. Invited chapter for Encyclopedia of Nanoscience and Nanotechnology, 2010
- S.G. Antimisiaris, K.A. Peptu, "Liposomes as Drug Delivery", In: Systems Medical Applications of Polymers, Edited by Marcel Popa, Raphael M. Ottenbrite, and Constantin V. Uglea, Volume 2: CHAPTER 8, Pages 1–35 (Copyright © 2011 by American Scientific Publishers)

Patents

1. *Liposomes containing particulate materials*. WO9509610 (A1) Publication date: 1995-04-13/US2002041895 - 2002-04-11 Inventor(s): G. Gregoriadis, S.G. Antimisiaris, I. Gursel.
2. *A method for immobilization of bioactive substances on surfaces for improving haemocompatibility*. Greek Patent, 2006, Inventor(s): S. G. Antimisiaris, I. Missirlis, G. Michanetzis, G. Koromila.
3. *Complex formulations for administration of microbicides or other categories of drugs via mucosal (or vaginal or rectal) routes, with high drug-loading capacity and controllable drug release rates*. Greek Patent, 20090100244, 2009, Inventor(s): S.G. Antimisiaris, P. Klepetsanis, S. Mourtas
4. *Treatment of Prostate tumors with arsonoliposomes*, US Provisional Patent, B1021US00, 2010, Inventors: S.G. Antimisiaris, P.V. Ioannou, M. Wei
5. *Novel curcumin derivatives with improved physicochemical properties and surface-decorated Nanoliposomes (with the derivatives) with very high affinity for Amyloid-β1-42 peptide*. Greek Patent application 20100100563, 2010, Inventor(s): S.G. Antimisiaris, F. Nicotra, S. Mourtas, C. Zona, B. LaFerla, A. Niaraki.

Metrics

(Google Scholar):

Citation indices	All	Since 2012
Citations	2332	1367
h-index	30	22
i10-index	61	37

(Scopus)

98 cited documents: Citations: 1893/1335* h-index: 27/23* (citations)

*excluding citations from all authors